vazquez pharmacy fl

FILE PHOTO: The logo of Gilead Sciences Inc pharmaceutical company is seen in Oceanside, California, U.S., where to buy generic carbozyne ca without prescription April 29, 2020. REUTERS/Mike Blake

(Reuters) – Gilead Sciences Inc said on Monday it had decided to stop a late-stage trial of its intravenous treatment, Veklury, in high-risk non-hospitalized patients with COVID-19.

The company said it no longer believes that developing a multiple day injection that requires administration in a healthcare setting addresses an unmet need for non-hospitalized patients.

The decision to stop the study is not due to efficacy or safety concerns, Gilead said.

Source: Read Full Article